Phase Ia/Ib Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs CAEL 101 (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Adverse reactions
- 09 Jan 2018 Status changed from active, no longer recruiting to completed.
- 12 Dec 2017 Results of the final analysis presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 11 Dec 2017 Results presented in a Fortress Biotech media release.